Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

MPI-176716 produces tumor regression in animal models of ovarian cancer

Jan. 15, 2004

BioStratum and Novo Nordisk to develop antibodies to laminin-5 for cancer

Jan. 15, 2004

Eloxatin approved for first-line treatment of advanced colorectal cancer

Jan. 15, 2004

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Jan. 15, 2004

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Jan. 15, 2004

A new phase II clinical trial to evaluate Davanat with 5-FU in refractory colorectal cancer

Jan. 14, 2004

Widespread use of alternative medicine in prostate cancer patients

Jan. 14, 2004

IND filed for phase I ThermoDox trial for liver cancer

Jan. 14, 2004

Approval granted to an expanded use of Eloxatin for metastatic colorectal cancer in Europe

Jan. 13, 2004

Phase I/II trial of MTC-MMC in NSCLC cleared to begin

Jan. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...